Shuliang Guo

Chongqing Medical University - Department of Respiratory and Critical Care Medicine

Chongqing

China

SCHOLARLY PAPERS

5

DOWNLOADS

303

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (5)

1.

The Production and Clinical Implications of SARS-CoV-2 Antibodies

Number of pages: 19 Posted: 30 Apr 2020
Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Three Gorges Central Hospital - Department of Medical Laboratory, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Health Statistics, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Three Gorges Central Hospital - Department of Health Management Centre, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Three Gorges Central Hospital - Department of Hepatopathy and Chongqing Medical University - Department of Respiratory and Critical Care Medicine
Downloads 127 (405,642)
Citation 1

Abstract:

Loading...

severe acute respiratory syndrome coronavirus 2; Corona virus disease 2019; IgG antibody; IgM antibody; clinical implication

2.

Early-Stage Vigilance of Novel Coronavirus Pneumonia

Number of pages: 19 Posted: 02 Mar 2020
Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Wuhan University of Science and Technology - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Wuhan University of Science and Technology - Department of Infectious Diseases, Wuhan University of Science and Technology - Department of Respiratory and Critical Care Medicine, Chongqing Medical University - Department of Health Statistics and Chongqing Medical University - Department of Respiratory and Critical Care Medicine
Downloads 85 (535,685)

Abstract:

Loading...

novel coronavirus pneumonia; Early-stage; vigilance

3.

The Prevalence and Risks of Major Co-Morbidities Among Patients with Pulmonary Tuberculosis in China from a Gender and Age Perspective: A Large-Scale Multi-Center Observational Study

Number of pages: 44 Posted: 14 Dec 2019
Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chongqing Public Health Medical Center, Shenyang Chest Hospital, Guangzhou Chest Hospital, Chest Hospital of Xinjiang Uygur Autonomous Region, Government of the People's Republic of China - Third People's Hospital of Kunming, Shandong Provincial Chest Hospital, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Jiangxi Chest Hospital, Chang Chun Infectious Diseases Hospital, Government of the People's Republic of China - Taiyuan Fourth People's Hospital, Fuzhou Pulmonary Hospital of Fujian, Tianjin Haihe Hospital, Government of the People's Republic of China - Third People's Hospital of Shenzhen, Chongqing Medical University - First Affiliated Hospital, Government of the People's Republic of China - Weifang No. 2 People's Hospital, Government of the People's Republic of China - Fifth People's Hospital of Suzhou, Zunyi Medical College, Government of the People's Republic of China - Fifth People's Hospital of Wuxi, TB Hospital of Siping City, Baoding Hospital for Infectious Disease, Xiamen University - First Affiliated Hospital, Shenyang Chest Hospital, Guangzhou Chest Hospital, Chest Hospital of Xinjiang Uygur Autonomous Region, Government of the People's Republic of China - Third People's Hospital of Kunming, Shandong Provincial Chest Hospital, Chang Chun Infectious Diseases Hospital, Government of the People's Republic of China - Taiyuan Fourth People's Hospital, Fuzhou Pulmonary Hospital of Fujian, Tianjin Haihe Hospital, Government of the People's Republic of China - Third People's Hospital of Shenzhen, Chongqing Medical University - First Affiliated Hospital, Government of the People's Republic of China - Weifang No. 2 People's Hospital, Government of the People's Republic of China - Fifth People's Hospital of Suzhou, Zunyi Medical College, Government of the People's Republic of China - Fifth People's Hospital of Wuxi, Baoding Hospital for Infectious Disease, Xiamen University - First Affiliated Hospital, Shenyang Chest Hospital, Guangzhou Chest Hospital, Chest Hospital of Xinjiang Uygur Autonomous Region, Government of the People's Republic of China - Third People's Hospital of Kunming, Shandong Provincial Chest Hospital, Chongqing Public Health Medical Center, Chang Chun Infectious Diseases Hospital, Tianjin Haihe Hospital, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Government of the People's Republic of China - Weifang No. 2 People's Hospital, Government of the People's Republic of China - Fifth People's Hospital of Suzhou, Zunyi Medical College, Baoding Hospital for Infectious Disease, Chongqing Public Health Medical Center, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute and Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute
Downloads 66 (617,725)

Abstract:

Loading...

Co-morbidity, Pulmonary Tuberculosis, Prevalence, Risks

4.

Central Nervous System Efficacy of Rezivertinib (BPI-7711) in Advanced NCLC Patients with EGFR T790m Mutation: A Pooled Analysis of Two Clinical Trials

Number of pages: 33 Posted: 20 Mar 2023
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - First Hospital, Shanxi Medical University - Department of Medical Oncology, Zhengzhou University - Department of Respiratory Medicine, Harbin Medical University - Department of Medical Oncology, Army Medical University - Institute of Cancer, Zhengzhou University - Department of Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Peking University - Department of Thoracic Medical Oncology, Qingdao University - Yantai Yuhuangding Hospital, Zhejiang University - The First Affiliated Hospital, Central South University - Thoracic Medicine Department II, Bengbu Medical College - First Affiliated Hospital, Sichuan University - Department of Thoracic Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Shandong First Medical University - Department of Oncology, Chongqing University Cancer Hospital - Department of Palliative Care, Chongqing University Cancer Hospital, Soochow University - Department of Pulmonary and Critical Care Medicine, Xingtai Medical College - Cancer Center, Nanjing Medical University - Department of Oncology, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Department of Pulmonary Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Huazhong University of Science and Technology - Tongji Medical College, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Xuzhou Medical University - Department of Radiotherapy, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Department of Respiratory and Critical Care Medicine, Shantou University - Department of Medical Oncology, Anhui Medical University - Department of Oncology, Soochow University - Second Affiliated Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 17 (971,245)

Abstract:

Loading...

Rezivertinib, BPI-7711, EGFR T790M mutation, CNS, NSCLC

5.

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent EGFR T790M Mutated NSCLC: A Phase IIb Study

Number of pages: 254 Posted: 11 May 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Shanxi Medical University - Department of Medical Oncology, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Sichuan Cancer Hospital - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Central South University - Thoracic Medicine Department II, Sichuan University - Department of Thoracic Oncology, Zhengzhou University - Department of Oncology, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Guangdong Medical University - Department of Oncology, Army Medical University - Institute of Cancer, Harbin Medical University - Department of Respiratory Medicine, Linyi Cancer Hospital - Department of Medical Oncology, Shandong First Medical University - Department of Oncology, Peking University - Department of Thoracic Medical Oncology, Xingtai Medical College - Cancer Center, People's Hospital of Deyang City - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Liuzhou People's Hospital - Department of Oncology, Dalian University - Department of Oncology, Central South University - Department of Respiratory Medicine, Zhengzhou University - Department of Respiratory Medicine, Henan University of Science and Technology - Department of Medical Oncology, Nanjing Medical University - Department of Respiratory Medicine, Government of the People's Republic of China - Department of Oncology, Xinjiang Medical University - Pulmonary Cancer Medicine, Henan University - Department of Oncology, China Medical University - Liaoning Cancer Hospital & Institute, Huazhong University of Science and Technology - Department of Medical Oncology, Chinese Academy of Sciences (CAS) - Department of Thoracic Surgery, Handan Central Hospital - Department of Oncology, Wenzhou Medical University - Second Affiliated Hospital, Tianjin Medical University - Department of Medical Oncology, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Chongqing University Cancer Hospital - Department of Palliative Care, Xuzhou Medical University - Department of Radiotherapy, Bengbu Medical College - Department of Medical Oncology, Zhengzhou University - Department of Medical Oncology, Chongqing Medical University - Department of Respiratory and Critical Care Medicine, Hubei University of Arts and Science - Department of Oncology, Zhejiang University - Department of Respiratory and Critical Care Medicine, Shantou University - Department of Medical Oncology, Nanjing Medical University - Department of Oncology, Anhui Medical University - Department of Oncology, Tongji University - Department of Respiratory and Critical Care Medicine, Beta Pharma, Inc., Beta Pharma (Shanghai) Co., Ltd. and Beta Pharma (Shanghai) Co., Ltd.
Downloads 8 (1,058,233)

Abstract:

Loading...

Rezivertinib, BPI-7711, NSCLC, EGFR T790M mutation, Third-generation EGFR TKI